Note: Descriptions are shown in the official language in which they were submitted.
1
POLYMORPHS AND SOLID STATES OF TIACUMICIN B
The present invention relates to new polymorphs and new solid states of
Tiacumicin
B. Tiacumicin B can be produced as disclosed in US4918174 or W02004014295.
There are several publications mentioning various polymorphs and crystals
related
to tiacumicins e.g. US8722863, US7863249, US8518899, CN103275153, J. Chem.
Soc. Perkin Trans, by Arnone and Nasini, 1987, page 1353-1359.
The following background is based on Florence et al, Physiochemical Principles
of
Pharmacy, 5th edition, August 2011:
The physical properties of the solid state seen in crystals and powders of
both drugs
and pharmaceutical excipients are of interest because they can affect both the
production of dosage forms and the performance of the finished product.
Crystalline solids can exist in several subphases, such as polymorphs,
solvates,
hydrates, and cocrystals. Polymorphs are different crystalline forms (at
different
free energy states) of the same compound. On the other hand, solvates,
hydrates and
co-crystals are similar in that they comprise a stoichiometric or significant
amount
of an additional compound. E.g., a drug together with an organic solvent (to
form a
solvate) or water (to form a hydrate), or another crystalline solid (to form
co-
crystals). Both types of compounds participate in the short-range and long-
range
orders of the crystal and therefore these subphases are regarded as single
crystalline
forms consisting of two types of molecules.
The nature of the crystalline form of a drug substance may affect its
stability in the
solid state, its solution properties and its absorption.
The solid state is important for a variety of reasons: morphology, particle
size,
polymorphism, solvation or hydration can affect filtration, flow, tableting,
dissolution and bioavailability. The crystals of a given substance may vary in
size,
the relative development of the given faces and the number and kind of the
faces (or
forms) present; that is, they may have different crystal habits. The habit
describes
the overall shape of the crystal in rather general terms and includes, for
example,
acicular (needle-like), prismatic, pyramidal, tabular, equant, columnar and
lamellar
types.
A more fundamental difference in properties may be found when the compounds
crystallise as different polymorphs. When polymorphism occurs, the molecules
arrange themselves in two or more different ways in the crystal; either they
may be
packed differently in the crystal lattice or there may be differences in the
orientation
or conformation of the molecules at the lattice sites. These variations cause
differences in the X-ray diffraction patterns of the polymorphs and this
technique is
Date Recue/Date Received 2022-01-20
2
one of the main methods of detecting the existence of polymorphs. The
polymorphs
have different physical and chemical properties; for example, they may have
different melting points and solubilities and they also usually exist in
different
habits.
Polymorphism is common with pharmaceutical compounds, but predictability of
the
phenomenon is difficult. Its pharmaceutical importance depends very much on
the
stability and solubility of the forms concerned. It is difficult, therefore,
to
generalise, except to say that where polymorphs of insoluble compounds occur
there
are likely to be biopharmaceutical implications.
The term -polymorph" as used herein is meant to embrace crystalline solid
states of
a pure compound including solvates, co-crystals and crystals.
However, polymorphs also have different crystal lattices and consequently
their
energy contents may be sufficiently different to influence their stability and
biopharmaceutical behaviour.
The most important consequence of polymorphism is the possible difference in
the
bioavailability of different polymorphic forms of a drug; particularly when
the drug
is poorly soluble. The rate of absorption of such a drug is often dependent
upon its
rate of dissolution. The most stable polymorph has the lowest solubility and
slowest
dissolution rate and consequently often a lower bioavailability than the
metastable
polymorph. It has been proposed that when the free energy differences between
the
polymorphs are small there may be no significant differences in their
biopharmaceutical behaviour as measured by the blood levels they achieve.
When some compounds crystallise they may entrap solvent in the crystal.
Crystals
that contain a solvent as part of the crystal lattice are called crystal
solvates, or
crystal hydrates when water is the solvent of crystallisation. Crystals that
contain no
water of crystallisation are termed anhydrates. Crystal solvates exhibit a
wide range
of behaviour depending on the interaction between the solvent and the crystal
structure. With some solvates the solvent plays a key role in holding the
crystal
together; for example, it may be part of a hydrogen-bonded network within the
crystal structure. These solvates are very stable and are difficult to
desolvate. When
these crystals lose their solvent they may collapse and re-crystallise in a
new crystal
form. We can think of these as polymorphic solvates. In other solvates, the
solvent
is not part of the crystal bonding and merely occupies voids in the crystal.
These
solvates lose their solvent more readily and desolvation does not destroy the
crystal
lattice.
Date Recue/Date Received 2022-01-20
3
Certain impurities can inhibit the growth pattern and favour the growth of
metastable polymorphs. Impurities in a crystallization process have been found
to
have vast effects on the morphology of the resulting crystal, with both
beneficial
and detrimental effects possible for the resultant product.
Impurities occur because materials are never 100% pure. An impurity compound
can often be incorporated at a regular site in the crystal structure.
Brief description of the figures
Figure 1A: Graphical XRPD of the Tiacumicin B starting material
Figure 1B: Graphical XRPD of the amorphous Tiacumicin B material
Figure 2: Graphical XRPD of the chlorobenzene crystal solvate of Tiacumicin B
Figure 3: XRPD of the n-propanol crystal solvate of Tiacumicin B
Figure 4: Graphical XRPD of the isopropanol crystal solvate of Tiacumicin B
Figure 5: Graphical XRPD of the methyl-ethyl-ketone crystal solvate of
Tiacumicin
B.
Figure 6: Graphical XRPD of the acetic acid crystal solvate of Tiacumicin B
Figure 7A: XRPD of high purity amorphous Tiacumicin material stored at 0 days
(top), 1 day (middle) and 7 days (bottom).
Figure 7B: XRPD of high purity amorphous Tiacumicin material stored at 0
months
(bottom), 1 month (middle) and 2 months (top).
Figure 7C: Glass transition temperature of high purity amorphous Tiacumicin
material by using Fox Equation.
Figure 8A: XRPD of the Tiacumicin solvate form a during storage.
Figure 8B: XRPD of the Tiacumicin solvate form a with peaks assigned with 20
values.
Figure 9A: XRPD of the Tiacumicin solvate form (3 during storage.
Figure 9B: XRPD of the Tiacumicin solvate form (3 with peaks assigned with 20
values.
Date Recue/Date Received 2022-01-20
4
Figure 10: Chromatogram of high purity Tiacumicin material.
A 4.6x150 mm Agilent Zorbax Eclipse XDB-C8 3.5 gm column was used and the
detector wavelength was 230 nm. A flow rate of 1.0 mL/min was used. Injection
volume was 10 gL and a total runtime of 21 min. The gradient program was 0
min:
60%A, 40%B. 3 min; 50% A, 50% B, 14 min 39% A, 61% B, 14.5 60% A, 40% B
until 21 min.
Mobile Phase A: 2.0 mL of trifluoroacetic acid was added to 2 L of Millli-Q
water.
Mobile Phase B: 1.0 mL of trifluoroacetic acid was added to 2 L of
acetonitrile.
App 0.2 mg of high purity Tiacumicin material was scaled into a HPLC vial and
diluted with citric buffer at pH 4.0+-0.1 that has been mixed with Acetonirile
at a
ratio of 2:3.
Figure 11: Comparison of XRPDs of three polymorphs according to the present
invention.
Summary of the invention:
The present invention concerns new polymorphs or solid states of Tiacumicin B.
The new polymorphs and new solid states are alternatives to the existing
polymorphs.
In one aspect, the present polymorph is a crystal solvate of Tiacumicin B
selected
from the propanol crystal solvate, the acetic acid crystal solvate, the
chlorobenzene
crystal solvate, the methyl-ethyl-ketone crystal solvate, the isopropyl-
acetate
solvate or the isopropanol crystal solvate.
In one aspect, the present polymorph is a crystal solvate of Tiacumicin B
selected
from the propanol crystal solvate, the acetic acid crystal solvate, the
chlorobenzene
crystal solvate, the methyl-ethyl-ketone crystal solvate, the isopropyl-
acetate
solvate or the isopropanol crystal solvate characterized by a XRPD displaying
a
peak at diffraction angle 20 of 19.9 0.1
In one aspect, the present polymorph is a crystal solvate of Tiacumicin B
selected
from the propanol crystal solvate, the acetic acid crystal solvate, the methyl-
ethyl-
ketone crystal solvate, the isopropyl-acetate solvate or the isopropanol
crystal
solvate characterized by a XRPD displaying a peak at diffraction angle 20 of
3.3
and 19.9 0.1
In one aspect, the present polymorph is a crystal solvate of Tiacumicin B
selected
from the propanol crystal solvate, the acetic acid crystal solvate or the
methyl-ethyl-
ketone crystal solvate characterized by a XRPD displaying a peak at
diffraction
angle 20 of 3.3 and 19.9 0.1
Date Recue/Date Received 2022-01-20
5
In one aspect, the n-propanol crystal solvate of Tiacumicin B is characterized
by a
XRPD displaying peaks at diffraction angles 20 of 3.3, 7.5, 7.7, 18.8 and 19.9
In one preferred aspect, the acetic acid crystal solvate of Tiacumicin B is
characterized by a XRPD displaying peaks at diffraction angles 20 of 6.7, 7.6,
18.7
and 19.9
In one aspect, the chlorobenzene crystal solvate of Tiacumicin B is
characterized by
a XRPD displaying peaks at diffraction angles 20 of 6.7, 18.8 and 19.9
In one preferred aspect, the methyl-ethyl-ketone crystal solvate of Tiacumicin
B is
characterized by a XRPD displaying peaks at diffraction angles 20 of 3.3, 7.5,
15.7
and 18.6
In one preferred aspect, the isopropanol crystal solvate of Tiacumicin B is
characterized by a XRPD displaying peaks at diffraction angles 20 of 6.5, 9.9,
18.6
and 19.8
In one aspect of the present invention, the new solid state is a high purity
amorphous Tiacumicin B material.
In one aspect of the present invention, the new solid state is a high purity
amorphous Tiacumicin B material with a Tg of ca 113 C as measured by DSC.
In one aspect of the present invention, the new solid state is a high purity
amorphous Tiacumicin B material comprising less than 5% w/w water.
In one aspect of the present invention, the new solid state is a high purity
amorphous Tiacumicin B material comprising less than 2% w/w water.
In one aspect of the present invention, the new solid state is a high purity
amorphous Tiacumicin B material comprising less than 0.5 w/w water.
In one aspect of the present invention, the new solid state is a high purity
amorphous Tiacumicin B material suitable for storage, comprising less than 2%
w/w
water and has a Tg of ca 113 C as measured by DSC.
In one aspect of the present invention, the new solid state is a high purity
amorphous Tiacumicin B material comprising more than 98% Tiacumicin B as
measured by HPLC, which is suitable for storage and comprises less than 2% w/w
water and has a Tg of ca 113 C as measured by DSC.
Date Recue/Date Received 2022-01-20
6
In one aspect of the present invention, a new polymorph of Tiacumicin B is
provided which is suitable for storage and displays XRPD with peaks at
diffraction
angles 20 of 16.6 and 19.9 0.1
In one aspect of the present invention, the new polymorph of Tiacumicin B is
an
acetic acid solvate which is suitable for storage and displays XRPD with peaks
at
diffraction angles 20 of 7.1, 16.6, 18.7 and 19.9 0.1
In one aspect of the present invention, the new polymorph of Tiacumicin B is
an
acetic acid solvate which is suitable for storage and displays XRPD with peaks
at
diffraction angles 20 of 7.1, 16.6, 18.7 and 19.9 0.1 substantially as shown
in
Figure 8B. This form is called Tiacumicin solvate Form cc.
In one aspect of the present invention, the new polymorph of Tiacumicin B is
an
isopropyl-acetate solvate which is suitable for storage and displays XRPD with
peaks at diffraction angles 20 of 7.3, 15.7, 16.6, 18.8, 19.9 and 20.2 0.1
In one aspect of the present invention, the new polymorph of Tiacumicin B is
an
isopropyl-acetate solvate which is suitable for storage and displays XRPD with
peaks at diffraction angles 20 of of 7.3, 15.7, 16.6, 18.8, 19.9 and 20.2
0.1
substantially as shown in Figure 9B. This form is called Tiacumicin solvate
Form f3.
In one aspect of the present invention, a new polymorph of Tiacumicin B is
provided which is suitable for storage and displays XRPD with peaks at
diffraction
angles 20 of 16.6, 18.8 and 19.9 0.1
In one aspect, the present polymorph is any crystal solvate of Tiacumicin B
characterized by a XRPD displaying a peak at diffraction angle 20 of 3.3, 9.9
and
18.6 0.1 or substantially as shown in Figure 11.
The various aspects and more of the present invention, including various
embodiments, will be described in further detail, with reference to the
detailed
description, examples and appended drawings.
Detailed description of the invention
According to one embodiment, Tiacumicin B can be produced by fermentation of
Dactylosporangium aurantiacum subspecies hamdenensis NRRL 18085 or
Actinoplanes deccanensis ATCC 21983.
The term -polymorph" as used herein is meant to embrace crystalline solid
states of
a pure compound including solvates, co-crystals and crystals.
Date Recue/Date Received 2022-01-20
7
A "pure compound" as used herein is meant to cover compounds with a HPLC
purity of at least 95%, or more preferred at least 97% and even more preferred
at
least 99%.
A "crystal solvate" as used herein is meant to cover polymorphs comprising a
significant amount of a solvent relative to the pure compound. By -significant
amount of a solvent relative to the pure compound" we mean a molar ratio of
solvent : compound from 1:2 or more.
Tiacumicin B is meant to cover the compound represented by the following
structure:
24 22 OH
s 9
23
7
\
F. 1(1 O HO,õõ stµµOilti!, 1? 6 \ OH
5 CI
0 <13
14 4 \ 0 "MO
"15
16 OH
17i c_...212:11 2
= 21
HO CI
s
iR
HO
The term "XRPD" is meant to embrace any method using X-rays for obtaining a
15 diffraction pattern of a solid state material. E.g. a method employing
copper Ka
radiation wavelength 1.54 A. The methods used herein are described in more
detail
in the experimental part.
A "peak" as used herein concerning XRPD is a relatively sharp rise and fall of
the
20 signal between two 20 values separated by a maximum of 2 degrees. Most
peaks in
the XRPDs herein have a relatively sharp rise and fall of the signal between
two 20
values separated by 1 degree or less.
A peak at a specific 20 value is to be understood as a peak displaying the
highest
intensity at this value 0.1 degrees. A crystal solvate displaying peaks at
20 values
x, y and z 0.1 means that the pertaining XRPD comprises peaks at x 0.1, y
0.1
and z 0.1.
Amorphous Tiacumicin B can be obtained from solutions comprising dissolved
Tiacumicin B by a variety of methods well known to the skilled person. E.g
adding
in an anti-solvent followed by solvent removal, sudden cooling of a saturated
solution, freeze drying/lyophilization of the solutions, spray drying of the
solutions
etc.
Date Recue/Date Received 2022-01-20
8
Solutions comprising dissolved Tiacumicin B can be obtained by dissolving
Tiacumicin B of any solid state or by purification of a fermentation broth
from
Dactylosporangium aurantiacum subspecies hamdenensis NRRL 1 8085 or
Actinoplanes deccanensis ATCC 21983.
A -high purity amorphous Tiacumicin material" is a material comprising 97% or
more of Tiacumicin B as measured by HPLC and displays a XRPD without any
peaks. It can be obtained as described in Example 1.
The high purity amorphous Tiacumicin material is hygroscopic with near linear
water uptake (see Figure 7C and Table 7 below), but it's not deliquescent. The
high
purity amorphous Tiacumicin material is suitable for storage as demonstrated
in
example 7 or even longer-term storage. Thus the high purity amorphous
Tiacumicin
.. material is relatively stable with respect to crystallization and suitable
for long-term
storage (e.g storage for 3 months, 6 months, 9 months etc.).
Table 7
Glass transition temperature of high purity amorphous Tiacumicin material by
using
Fox Equation:
Date Recue/Date Received 2022-01-20
9
%H20 Tg (QC) Tg(K) R H (%)
0.01% 113 386 0%
0.5% 108 381.4 6%
1.0% 104 376.9 13%
1.5% 100 372.5 19%
2.0% 95 368..2 26%
2:51% 91 364.0 32%
3.0% 87 359.9 39%
3,51% 83 355.9 45%
79 352.0 51%
4.51% 75 348.2 58%
5.0% 71 344.4 64%
68 340.7 71%
6.0% 64 337.1 77%,
61 333.6 84%
7.01% 57 330:2 90%
7.5% 54 326.8 96%
8:0% 50 323.5 103%
A -crystal solvate of Tiacumicin B" is any crystal solvate comprising pure
Ticaumicin B.
Pure Tiacumicin B as used herein is meant to cover Tiacumicin B with a HPLC
purity of at least 95%, or more preferred at least 97% and even more preferred
at
least 99% by detection at 230 nm.
Tiacumicin B can be produced as disclosed in the prior art but is also
commercially
available (e.g. Bioaustralis Fine Chemicals). The crystalline Tiacumicin B
starting
material is also commercially available (e.g Brightgene Bio-
MedicalTechnology).
Experimental data:
XRPD methods:
Stoe Stadi P; MythenIK Detector; Cu-Kal radiation; standard measurement
conditions: transmission; 40 kV and 40 mA tube power; curved Ge
monochromator; 0.02 20 step size, 12 s step time, 1.5-
50.5 20 scanning range; detector mode: step scan; 1 20 detector step;
Date Recue/Date Received 2022-01-20
10
standard sample preparation: 10 to 20 mg sample was placed between two
acetate foils; sample holder: Stoe transmission sample holder; the sample
was rotated during the measurement. Filenames of patterns recorded on this
instrument consist of a three-digit number followed by a letter.
or
Bruker D8; Copper K. radiation, 40 kV/ 40 mA; LynxEye detector, 0.02 20
step size, 37 s step time.
Sample preparation:
The samples were generally measured without any special treatment other
than the application of slight pressure to get a flat surface. Silicon single
crystal sample holder types: a) standard holder for polymorphism screening,
0.1 mm deep, less than 20 mg sample required; b) 0.5 mm deep, 12 mm
cavity diameter for c. 40 mg; c) 1.0 mm deep, 12 mm cavity diameter for c.
80 mg. All samples measured on the Bruker D8 are rotated during the
measurement.
Example 1: Amorphous Tiacumicin B
Crystalline Tiacumicin B starting material (see XRPD in Figure 1A) with a HPLC
purity of ca 99% and a water content of less than 1% w/w was dissolved in
.. water/THF (5:1, v:v) and lyophilized. The lyophilized product was amorphous
(see
Figure 1B).
Example 2: Chlorobenzene crystal solvate of Tiacumicin B
Amorphous Tiacumicin B obtained in example 1 (69 mg) was mixed with 1.5 ml n-
heptane/chlorobenzene 1:2 (v:v). The suspension was shaken at r.t. for 24
hours.
Finally, 50% of the solvents were evaporated at r.t. under gentle N2 flow (no
flow
control). The resulting solid was filtered off. The wet material thus obtained
comprised 23% w/w chlorobenzene as measured by TG-FTIR. XRPD of the
chlorobenzene crystal solvate of Tiacumicin B is shown in Figure 2 and Table 2
below.
Table 2 below shows XRPD of the chlorobenzene crystal solvate of Tiacumicin B
in table format showing the relative intensity of the peaks, highest peak 100.
The
peaks are designated w for weak intensity, m for medium intensity, s for
strong
intensity and vs for very strong intensity.
Table 2
XRPD of the chlorobenzene crystal solvate in table format.
i 207; d value [A] latenUty [Cps' Intensity 94
3.
2
6.66 91.5
Date Recue/Date Received 2022-01-20
11
7.27 121 rn 29_9
7.76 114 rn 17_1
9.94 8.9 n 279
10.75 82 A 10_9
11.48 77 A 149
11.73 7.5 rn 181
1261 7D tri 14.1
1285 & rn 214
13.25 6.7 r 173
13.65 6.5 rn 161
14.13 63 A 125
1465 6.0 rn 16S
15.10 5.86 rn 203
15.58 5E0 w 116
1623 516 rn 21_9
16.97 5.22 s 49_1
17.59 5114 w 10_1
18.20 407 w 10/
1877 4_72 vs 100E
19.93 445 s 44.4
20.34 436 A 13E
20.77 4.27 s 313
2203 4.03 n 24.5
2241 396 A 124
2267 3.92 w 115
2105 3_06 m 19_9
23.55 377 A 145
24.50 3E3 w 129
2529 3.52 orLB
25.83 145 A 113
25.63 334 w BE
2E09 329 w 9_0
27.51 324 w 8.0
2051 3.13 A 103
30.07 2.97 w 10_1
31.43 284 w OE
31.75 2.02 w 7E
32.79 213 A 9_13
33.43 2613 A 6_3
Example 3: n-propanol crystal solvate of Tiacumicin B
Amorphous Tiacumicin B obtained in example 1 (100mg) was mixed 2 ml n-
propanol to form a slurry. The suspension was stirred at r.t. for
24 hours. Finally, the solvent was evaporated at r.t. under gentle N2 flow.
The wet
material obtained comprised 4% w/w n-propanol as measured by TG-FTIR.
XRPD of the n-propanol crystal solvate of Tiacumicin B is shown in Figure 3
and
Table 3.
Table 3 below shows XRPD of the n-propanol crystal solvate of Tiacumicin B
in table format showing the relative intensity of the peaks, highest peak 100.
The
peaks are designated w for weak intensity, m for medium intensity, s for
strong
intensity and vs for very strong intensity.
Date Recue/Date Received 2022-01-20
12
Table 3
XRPD of the n-propanol crystal solvate in table format:
Angle d value [Al Intensity Intensity%
[020] [Cps]
3.22 2613
7 f 1 11.3 vs 79.2
i 0'0 i 1,6,
9 94 &SI Mk :i I 3
!O.54 8.4. m 7.8
10.64 83 ni, 23.1
I 1 92, TA. l'illi I 5.4:
12.17 7_3 in 20.0
13 26 6.7 w 12 Y
1.3.07 6.3 In 20:3
14 31) 62
14.4.4 61 20.1
,
14 87 '.7.- 9'7'r li!
I 5.391 E, 75 a 30.7
15.79 5 r., I s 32.4
w
1r, ;-;1;) r% -:i na !.1 4
17.32, E I 1 w ;0.2
ip, 71.7., 4 7 vai LOD 0
19 04 4 63 w 114.4
19.3E; gII '.:=3 w
19 91 4 4G $ 43 2
20.21 41 29 ni 29:4
21 13 4 -.'1) ra r wr =.,l;
21.71 A 09 ur ;2.8
22
23.n3 2 ;213 in 16.1
24 05 7.70 w 1'3 '1
24 41.2 .3.6S w
741, ., wi
25.23 7t 33 w 10 7
V411 I "I
28.71 3 ; I w ;0.9
.29 .27, 7 gg. w
'30 04 ' =_I:,' w ?
30.66 :2 91 w 9.1
W Ft.6
34.83 2 ::7 ,x. 3.3
Date Recue/Date Received 2022-01-20
13
Example 4: iso-propanol crystal solvate of Tiacumicin B
Amorphous Tiacumicin B obtained in example 1 (73 mg) was mixed with 1.5 ml
iso-propanol to form a slurry. The suspension was shaken at r.t. for 24 hours.
Finally, 50% of the solvents were evaporated at r.t. under gentle N2 flow. The
slurry
was then filtered and the wet material obtained comprised 17% w/w iso-propanol
as
measured by TG-FT1R. The isopropanol was lost in two steps; first 11% w/w and
then 6% w/w.
XRPD of the iso-propanol crystal solvate of Tiacumicin B is shown in Figure 4
and
Table 4 below.
Table 4: XRPD of the isopropanol crystal solvate of Tiacumicin B
in table format showing the relative intensity of the peaks, highest peak 100.
The
peaks are designated w for weak intensity, m for medium intensity, s for
strong
intensity and vs for very strong intensity.
Date Recue/Date Received 2022-01-20
14
Table 4
XRPD of the iso-propanol crystal solvate in table format:
Angle d value Intensity Intensity%
2-,Thelac Angstrom Cpz,
3.35 26.4 vi 8.1
6.49 13.43 s 561
7.78 '11 .1 w 55
32.9
10.04 1:14 w 8.5
H.46 71 m 224
12.59 7.0 m 2E1
12.83 6.9 w 8..0
13 . 33 6.6 vw 3,5
1355 g q
_.._ w 5.5
14:39 6.1 v., 6.4
1557 5:69 VW 3.3
15_86 5_58 vw 4.9
1545 5_39 m 211
1578 5.28 w 5.8
17.66 5.02 vw 31
18.64 4:76 vs 100.0
13.94 458 w 13.2
19.38 4.58 vw 4:6
19.79 448 s 375
20.04 443 w 5:7
20.50 4.33 m 19,.8
21.15 420 'vw 4.2
21.67 4.10 w 6.6
22.15 4011 w 13.0
22.68 3.92 w 8.1
22_99 357 w 6.3
23.28 352 w 6.3
2345 :3:79 vw 4.9
24.03 3.70 vw 4.9
24.54 3.62 vw 3.2
25.29 3.52 w 5.6
25.81 3.45 vw 3.3
28:31 3.15 w 7:6
2891 309 'vw 3_4
29.21 3.06 'vw 4.7
29.41 3.03 %Am 3.9
29.91 2.93 w 52
30.93 2.89 vw 2.6
31.98 2.30 VW 3.3
32.63 2.74 'vw 2.9
34.61 2.59 'vw 3.0
3730 2_38 'vw 2.3
38.40 2.34 'vw 4.0
Date Recue/Date Received 2022-01-20
15
Example 5: methyl-ethyl-ketone (MEK) crystal solvate of Tiacumicin B
Amorphous Tiacumicin B obtained in example 1 (71 mg) was mixed with 1.5 ml n-
heptane/MEK 1:2 (v:v). The suspension was shaken at r.t. for 24 hours.
Finally,
50% of the solvents were evaporated at r.t. under gentle N2 flow (no flow
control).
The resulting solid was filtered off. The wet material obtained comprised 6%
iso-
propanol as measured by TG-FT1R. XRPD of the methyl-ethyl-ketone crystal
solvate of Tiacumicin B is shown in Figure 5 and Table 5.
Table 5 below shows XRPD of the methyl-ethyl-ketone crystal solvate of
Tiacumicin B in table format showing the relative intensity of the peaks,
highest
peak E 100. The peaks are designated w for weak intensity, m for medium
intensity,
s for strong intensity and vs for very strong intensity.
Table 5
XRPD of the MEK crystal solvate in table format:
Angle d value [A] Intensity Intensity%
[020] [Cps]
3 3Z .71.. 6 3 ES 6
7 4H I 1 3 vs I 0,:l 3
10,5 M 2c1 2
9.94 eln 4 32 .0
lo.4.1 e.4 s
O.62 6 3 s 38.8
11 89 74 M 26.7
1.:,! 13 ( ::1 3
in
13.23 .1 M 2.2
14 29 'l 2 * 325
15.72 4 5149
l'-, R 1 .6_27 m
4 I M
11.9. i311 4. 103 a r4.2
p3, 8.0fi 4 70 in 25 7
19 75 4.49 ''S 37.7
20.07 4.42 m 2'i 0
nri
21 71 4. Cl` I M
22 12 4 01 m 22.0
22.65. .3. 94 M 29.3
:22 'LI2 3.88 M 207
13 ',t%'i' 3.71 m 20
1 im ws
::30 50 --, ,-_,,;w
:14.8a 2 5.8 w LOS
Date Recue/Date Received 2022-01-20
16
Example 6: Acetic acid crystal solvate of Tiacumicin B
Crystalline Tiacumicin B starting material (100 mg) with a HPLC purity of ca
99%
and a water content of less than 1% w/w was mixed with 2 ml water/acetic acid
(1:1, v:v) to form a slurry. The suspension was stirred at r.t. for 48 hours.
Finally,
the solvents were evaporated at r.t. under gentle N2 flow. The obtained
material
comprised 6% w/w acetic acid as measured by TG-FTIR. XRPD of the acetic acid
crystal solvate of Tiacumicin B is shown in Figure 6 and Table 6.
Table 6 below shows XRPD of the acetic acid crystal solvate of Tiacumicin B in
table format showing the relative intensity of the peaks, highest peak E 100.
The
peaks are designated w for weak intensity, m for medium intensity, s for
strong
intensity and vs for very strong intensity.
Table 6
XRPD of the acetic acid crystal solvate in table format:
Angle d value [A] Intensity Intensity%
[020] [Cps]
V_. 4
70?' 12c. S =14
I I 1 0
9 9 I:I '1
IC
I I '--1 7 -,` 5 36 a
I I ,:,_; 7 = in 285
I = 7
u5
1 4-7-6' S 11111 2F, ,'=
IM _7-=,; i
12: 38
f .,,. M :77 4
1 c p.-,=r
1;E I I J., ,_*,,J 011
I 9 U I al r F ,1"' a :,:_l 4.
4. 41' S 30.7
2C 1- =:.* 4 2 ri MI
2 I 12 =.: .2L1 m ':''''r n
22 02 rn .2-I
IM
23_62 "3 T ... tril .2 1
I in
:3 Y , i in It ..i.
7'; 32 3 '..=-= m 19 8
3,22 ..,. 14.0
312 III 1 7 5
Date Recue/Date Received 2022-01-20
17
Example 7: Stability of high purity amorphous Tiacumicin material
Several samples of high purity amorphous Tiacumicin B material were stored at
40 C/75% relative humidity. XRPDs obtained at start, 24 hours, 7 days and 1
month
show amorphous material (se Figure 7A).
Several samples of high purity amorphous Tiacumicin B material were stored at
room temperature under normal light conditions. XRPDs obtained at start, 1
month
and 2 months show amorphous material (se Figure 7B). XRPDs of high purity
amorphous Tiacumicin B material also show amorphous material at 3 months.
Example 8: Crystal solvate of Tiacumicin B (form a)
Crystalline Tiacumicin B starting material (220 mg) with a HPLC purity of ca
99%
and a water content of less than 1% w/w was mixed with 4.5 ml water/acetic
acid
(1:1, v:v) to form a slurry. The suspension was stirred at r.t. for 96 hours.
Finally,
the resulting solid was filtered off and dried in air (5 min).
The obtained material comprised 16% w/w acetic acid as measured by TG-FTIR.
XRPD of the storage suitable form a of Tiacumicin B is shown in Figure 8A.
XRPD
of the storage suitable form a of Tiacumicin B with peaks assigned with 20
values is
shown in Figure 8B. XRPD of the storage suitable form a of Tiacumicin B in
table
format of is shown in Table 8 below.
Date Recue/Date Received 2022-01-20
18
Table 8
XRPD in table format of Tiacumicin solvate form cc.
Intensity
Angle d value Intensity yo
2-Theta Angstrom rel yo
3,40 26,0 w 6,2
7,12 12,4 vs 93,3
8,48 10,4 vw 2,0
10,16 8,7 w 10,0
10,31 8,6 m 20,7
10,78 8,2 w 13,6
11,65 7,6 w 14,6
12,47 7,1 m 21,9
13,71 6,5 w 7,6
13,95 6,3 w 9,2
14,47 6,1 w 6,8
14,77 5,99 w 11,1
15,72 5,63 w 5,2
16,66 5,32 s 40,3
18,70 4,74 vs 100,0
18,97 4,68 w 7,2
19,90 4,46 s 47,9
20,38 4,36 w 9,7
20,89 4,25 w 6,9
21,08 4,21 w 10,1
21,63 4,11 w 11,3
22,03 4,03 m 16,1
22,42 3,96 vw 4,9
22,97 3,87 w 7,7
23,38 3,80 w 10,9
23,78 3,74 w 5,9
24,51 3,63 w 7,5
25,09 3,55 w 9,2
25,33 3,51 vw 4,4
26,00 3,42 vw 4,2
26,38 3,38 vw 4,2
27,31 3,26 vw 1,6
27,63 3,23 vw 1,9
28,54 3,13 w 7,6
28,73 3,10 w 6,2
31,90 2,80 vw 2,9
32,78 2,73 vw 4,9
35,02 2,56 vw 3,6
Example 9: Crystal solvate of Tiacumicin B (form 13)
Crystalline Tiacumicin B starting material (100 mg) with a HPLC purity of ca
99%
and a water content of less than 1% w/w was mixed with isopropyl-acetate (1:1,
v:v) to form a slurry. The suspension was stirred at r.t. for 48 hours.
Finally, the
solvents were evaporated at r.t. under gentle N2 flow. Crystalline Tiacumicin
B
Date Recue/Date Received 2022-01-20
19
starting material (220 mg) with a HPLC purity of ca 99% and a water content of
less
than 1% w/w was mixed with 3 ml isopropyl acetate (most solid dissolved) and 3
ml
n-heptane to form a slurry. The suspension was stirred at r.t. for 96 hours.
Finally,
the resulting solid was filtered off and dried in air (5 min).
The obtained material comprised 9% w/w isopropylacetate as measured by TG-
FTIR. XRPD of the storage suitable form (3 of Tiacumicin B is shown in Figure
9A.
XRPD of the storage suitable form (3 of Tiacumicin B with peaks assigned with
20
values is shown in Figure 9B. XRPD of the storage suitable form (3 of
Tiacumicin B
in table format of is shown in Table 9 below.
Table 9
XRPD in table format of Tiacumicin solvate form (3.
Intensity
Angle d value Intensity yo
2-Theta Angstrom rel. yo
3,28 26,9 w 5,9
4,91 18,0 w 6,6
6,51 13,6 vw 4,1
7,32 12,1 m 17,2
9,79 9,0 w 7,9
10,59 8,3 w 9,8
11,46 7,7 vw 2,6
13,63 6,5 vw 2,8
15,28 5,79 vw 4,3
15,68 5,65 m 24,4
16,61 5,33 w 5,5
18,82 4,71 vs 100,0
19,10 4,64 vw 4,1
19,44 4,56 vw 4,3
19,95 4,45 w 8,8
20,21 4,39 m 26,9
21,80 4,07 w 5,0
22,64 3,92 w 5,8
23,32 3,81 w 6,1
28,80 3,10 vw 4,7
29,33 3,04 vw 3,2
Date Recue/Date Received 2022-01-20
